Quantum Genomics Overview
- Founded
-
2006

- Status
-
Public
- Employees
-
9

- Stock Symbol
-
ALQGC

- Investments
-
1
- Share Price
-
$0.18
- (As of Wednesday Closing)
Quantum Genomics General Information
Description
Quantum Genomics is a biopharmaceutical company engaged in developing new products for unmet needs in the field of cardiovascular diseases, high blood pressure, and heart failure. The company products include firibastat, QGC006, QGC011, and others.
Contact Information
- 33 rue Marbeuf
- 75008 Paris
- France
Quantum Genomics Timeline
Quantum Genomics Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.18 | $0.18 | $0.12 - $4.70 | $6.13M | 34.5M | 514K | -$0.92 |
Quantum Genomics Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 43,085 | 106,208 | 148,559 | 51,698 |
Revenue | 1,010 | 137 | 1,372 | 0 |
EBITDA | (27,350) | (22,359) | (15,795) | (12,032) |
Net Income | (24,775) | (19,574) | (13,151) | (10,163) |
Total Assets | 28,265 | 25,572 | 42,990 | 16,922 |
Total Debt | 3,546 | 3,400 | 2 | 2 |
Quantum Genomics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Quantum Genomics Comparisons
Industry
Financing
Details
Quantum Genomics Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cardurion Pharma | Venture Capital-Backed | Burlington, MA | 00 | 00000 | 0000000000 0 | 00000 |
0000000 | Private Equity-Backed | Prague, Czech Republic | 0000 | 00.000 | 000000000 | 00.000 |
Quantum Genomics Patents
Quantum Genomics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2013336738-A1 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | Active | 22-Oct-2012 | 0000000000 | |
AU-2013336738-B2 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | Active | 22-Oct-2012 | 0000000000 | |
CA-2884914-A1 | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine | Active | 22-Oct-2012 | 0000000000 | |
EP-2722327-A1 | Crystalline phase of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with l-lysine | Inactive | 22-Oct-2012 | 0000000000 | |
EP-2909169-B1 | Crystalline phase of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) with l-lysine | Active | 22-Oct-2012 | C07C319/28 |
Quantum Genomics Executive Team (8)
Quantum Genomics Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
000000 0000000000 | Quantum Genomics | Board Member | 000 0000 |
000000000 0é0000 | Self | Board Member | 000 0000 |
0000-00000000 0000 | Quantum Genomics | Chief Executive Officer & Board Member | 000 0000 |
0000000 000000 | Quantum Genomics | Board Member & Managing Director of International Multifinance | 000 0000 |
Quantum Genomics Signals
Quantum Genomics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Quantum Genomics Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000000 | 29-Oct-2007 | 0000000000 | Consulting Services (B2B) | 000000 0é |
Quantum Genomics ESG
Risk Overview
Risk Rating
Updated December, 21, 2022
28.14 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile

Biotechnology
Subindustry
00 of 465
Rank
Percentile

Quantum Genomics Exits (1)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
0000000000 | 29-Oct-2007 | 000000000000000000 | Completed |
|